Fierce Pharma April 22, 2024
Bristol Myers Squibb was the first major biopharma company to take notice of innovative cell therapy contract manufacturer Cellares, participating to a $255 million series C funding round in August of last year.
Eight months later, BMS has expanded its partnership with the five-year-old South San Francisco company, signing a $380 million deal to reserve CAR-T manufacturing space.
The agreement, which includes upfront and future milestone payments, gives BMS exclusive access to an unspecified number of Cellares’ compact automated cell therapy manufacturing units in the United States, Europe and Japan. It will allow BMS to expand its capacity to produce potential CAR-T blockbusters Breyanzi and Abecma, as well as potential future candidates.
Launch of BMS’s two blood cancer...
Today's Sponsors
Today's Sponsor